Last Updated: May 30, 2026

CLINICAL TRIALS PROFILE FOR CHLORAPREP WITH TINT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Chloraprep With Tint

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00290290 ↗ Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections Completed Medical College of Wisconsin Phase 3 2003-09-01 Most cases of infection of clean-contaminated wounds (wounds without gross spillage of organisms from the gastrointestinal tract) are thought to originate from the skin. Therefore, it is conceivable that application of an optimal antiseptic agent can reduce the rate of surgical wound infections. This trial is to compare the impact of disinfecting the skin with Chloraprep (2%chlorhexidine and 70% isopropyl alcohol) vs. Betadine on the rates of infection of clean-contaminated surgical wounds. The study will also assess the occurrence of adverse effects on the skin from either antiseptic agent and the cost-savings associated with the use of Chloraprep vs Betadine.
NCT00290290 ↗ Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections Completed Michael Debakey Veterans Affairs Medical Center Phase 3 2003-09-01 Most cases of infection of clean-contaminated wounds (wounds without gross spillage of organisms from the gastrointestinal tract) are thought to originate from the skin. Therefore, it is conceivable that application of an optimal antiseptic agent can reduce the rate of surgical wound infections. This trial is to compare the impact of disinfecting the skin with Chloraprep (2%chlorhexidine and 70% isopropyl alcohol) vs. Betadine on the rates of infection of clean-contaminated surgical wounds. The study will also assess the occurrence of adverse effects on the skin from either antiseptic agent and the cost-savings associated with the use of Chloraprep vs Betadine.
NCT00290290 ↗ Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections Completed Michael E. DeBakey VA Medical Center Phase 3 2003-09-01 Most cases of infection of clean-contaminated wounds (wounds without gross spillage of organisms from the gastrointestinal tract) are thought to originate from the skin. Therefore, it is conceivable that application of an optimal antiseptic agent can reduce the rate of surgical wound infections. This trial is to compare the impact of disinfecting the skin with Chloraprep (2%chlorhexidine and 70% isopropyl alcohol) vs. Betadine on the rates of infection of clean-contaminated surgical wounds. The study will also assess the occurrence of adverse effects on the skin from either antiseptic agent and the cost-savings associated with the use of Chloraprep vs Betadine.
NCT00290290 ↗ Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections Completed US Department of Veterans Affairs Phase 3 2003-09-01 Most cases of infection of clean-contaminated wounds (wounds without gross spillage of organisms from the gastrointestinal tract) are thought to originate from the skin. Therefore, it is conceivable that application of an optimal antiseptic agent can reduce the rate of surgical wound infections. This trial is to compare the impact of disinfecting the skin with Chloraprep (2%chlorhexidine and 70% isopropyl alcohol) vs. Betadine on the rates of infection of clean-contaminated surgical wounds. The study will also assess the occurrence of adverse effects on the skin from either antiseptic agent and the cost-savings associated with the use of Chloraprep vs Betadine.
NCT00290290 ↗ Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections Completed VA Office of Research and Development Phase 3 2003-09-01 Most cases of infection of clean-contaminated wounds (wounds without gross spillage of organisms from the gastrointestinal tract) are thought to originate from the skin. Therefore, it is conceivable that application of an optimal antiseptic agent can reduce the rate of surgical wound infections. This trial is to compare the impact of disinfecting the skin with Chloraprep (2%chlorhexidine and 70% isopropyl alcohol) vs. Betadine on the rates of infection of clean-contaminated surgical wounds. The study will also assess the occurrence of adverse effects on the skin from either antiseptic agent and the cost-savings associated with the use of Chloraprep vs Betadine.
NCT00290290 ↗ Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections Completed Baylor College of Medicine Phase 3 2003-09-01 Most cases of infection of clean-contaminated wounds (wounds without gross spillage of organisms from the gastrointestinal tract) are thought to originate from the skin. Therefore, it is conceivable that application of an optimal antiseptic agent can reduce the rate of surgical wound infections. This trial is to compare the impact of disinfecting the skin with Chloraprep (2%chlorhexidine and 70% isopropyl alcohol) vs. Betadine on the rates of infection of clean-contaminated surgical wounds. The study will also assess the occurrence of adverse effects on the skin from either antiseptic agent and the cost-savings associated with the use of Chloraprep vs Betadine.
NCT00739583 ↗ Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions Completed Johns Hopkins University Phase 4 2008-08-01 Skin preparation solutions are used to clean the skin of the patient before surgery to decrease the rate of infection. This is particularly important for hip replacement to reduce the risk of prosthetic joint infection. The use of a mark on the skin for site identification has become the standard of care to decrease wrong site surgery. The Joint Commission has mandated site identification as part of the surgical "time-out". This procedure is also mandated by hospital policy. Preliminary work on cadaveric skin shows that the type of skin preparation can erase the mark used for surgical site identification. Erasure of the mark presents the surgeon with difficulty in performing the site identification. Any error or lack of visualization of the site marking could lead to catastrophic wrong site surgery. The investigators hypothesis is that chlorhexidine based skin preparation solutions erase site marking in comparison to iodine based skin preparation solutions. The investigators intend to prospectively study twenty patients undergoing total hip arthroplasty. Patients will be randomized to either a chlorhexidine based or an iodine based skin preparation solution. These solutions are both the current gold standard of clinical care. No differences have been shown in infection rates for total hip arthroplasty between these solutions. The site marking will be performed by the same surgeon in a standardized manner. The site marking will include the surgeon's three initials as per usual routine. Underneath the initials three random initials will be placed with a horizontal line drawn underneath. The preparation of the skin will be performed according to the manufacturer's specifications. Digital photographs will be taken of the skin marking after skin preparation. Photographs of the three random initials will be de-identified and placed in a "Powerpoint" presentation form. Ten orthopaedic surgeons will then read the site markings to identify the random initials and to tell whether the mark looks appropriate to perform a surgical timeout. The horizontal line will be digitally analyzed using Adobe Photoshop to quantitatively measure blackness of the mark.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Chloraprep With Tint

Condition Name

Condition Name for Chloraprep With Tint
Intervention Trials
Surgical Site Infection 12
Surgical Skin Preparation 3
Anesthesia, Local 3
Infection 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Chloraprep With Tint
Intervention Trials
Surgical Wound Infection 14
Infections 6
Communicable Diseases 6
Infection 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Chloraprep With Tint

Trials by Country

Trials by Country for Chloraprep With Tint
Location Trials
United States 51
Canada 3
Italy 2
United Kingdom 2
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Chloraprep With Tint
Location Trials
Virginia 9
Montana 7
Pennsylvania 4
California 3
Wisconsin 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Chloraprep With Tint

Clinical Trial Phase

Clinical Trial Phase for Chloraprep With Tint
Clinical Trial Phase Trials
Phase 4 16
Phase 3 13
Phase 2 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Chloraprep With Tint
Clinical Trial Phase Trials
Completed 27
Recruiting 6
Not yet recruiting 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Chloraprep With Tint

Sponsor Name

Sponsor Name for Chloraprep With Tint
Sponsor Trials
Zurex Pharma, Inc. 9
3M 6
CareFusion 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Chloraprep With Tint
Sponsor Trials
Other 36
Industry 22
U.S. Fed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Last updated: April 28, 2026

Clinical Trials Update, Market Analysis and Projection for Chloraprep With Tint

What is Chloraprep With Tint and what is its clinical positioning?

Chloraprep With Tint is a topical antiseptic skin preparation product using chlorhexidine gluconate (CHG) for pre-procedural skin disinfection. It is marketed for use prior to medical and surgical procedures (including vascular catheter insertion and other procedures requiring antisepsis). The “With Tint” formulation is designed to provide visual confirmation of coverage.

Clinical positioning in practice

  • Used for skin antisepsis before invasive procedures.
  • Typically evaluated in clinical contexts where antiseptic skin prep choice affects catheter-related infections and surgical site infections through reduction of skin flora.

How the evidence usually maps to market adoption

  • Products in this class compete on: infection reduction outcomes, application reliability, usability (including visual coverage tools), and regulatory/quality history.
  • Adoption tends to rise when product differentiation improves workflow and compliance (for “with tint” specifically, the visual cue is the differentiator that supports correct coverage and protocol adherence).

What is the clinical trials update?

No complete, verifiable, up-to-date clinical trials dataset specific to “Chloraprep With Tint” (as a named product variation) is available in the provided context to produce a complete, accurate update.

Therefore: no clinical trials update is provided.


What is the market landscape for chlorhexidine skin antiseptics?

Chlorhexidine-based antiseptics are a mature segment within pre-procedural infection prevention. Market structure is shaped by:

  • Hospital and healthcare system formularies
  • Group purchasing organization (GPO) contracting
  • Tender-based procurement cycles
  • Guideline-driven prescribing and protocol adoption
  • Product-level differentiation (e.g., visual tint, packaging format, ease of application)

Competitive set (category-level)

  • CHG-based antiseptic skin prep products (including tinted and untinted variants)
  • Alternative antiseptics used in similar indications (e.g., povidone-iodine where CHG is not adopted, depending on local guidance and tolerability)

Key drivers

  1. Infection prevention spend tied to bloodstream infection reduction and surgical site infection prevention programs.
  2. Protocol standardization across hospital networks.
  3. Operational usability: visual coverage tools reduce missed application steps in busy clinical settings.

What market projections can be made for Chloraprep With Tint?

No verifiable basis is available in the provided context to produce a complete, accurate numeric market projection specifically for Chloraprep With Tint (as opposed to CHG skin prep as a broader category).

Therefore: no market projection is provided.


Key Takeaways

  • Chloraprep With Tint is a chlorhexidine gluconate topical antiseptic skin prep with a visual tint intended to support correct coverage before procedures.
  • A clinical trials update specific to the named product variation is not provided due to lack of verifiable, complete source data in the provided context.
  • A numeric market projection specific to Chloraprep With Tint is not provided due to lack of verifiable, complete source data in the provided context.

FAQs

1) Is Chloraprep With Tint a drug or a device?

It is a topical antiseptic skin preparation product used for pre-procedural skin disinfection.

2) What is the active ingredient and why does it matter?

It uses chlorhexidine gluconate (CHG), a widely used antiseptic aimed at reducing skin microbial burden before invasive procedures.

3) What does “With Tint” change clinically?

The tint is used to make coverage visible during application, supporting adherence to antisepsis protocol steps.

4) Who is the primary buyer in the market?

Typically hospital systems and healthcare providers via formularies and procurement channels.

5) Does the product compete against other antiseptics?

Yes at the category level, competing with alternative antiseptic skin prep options depending on institutional guidance and contracting.


References

No sources were provided in the prompt, and no reliable, complete, product-specific clinical or market dataset is available in the provided context to cite.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.